Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT01717859
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.

Study Details

The purpose of this research study is to determine if a change in inflammation or baseline inflammation seen on the ultrasound is a good indicator of how rheumatoid arthritis patients respond to TCZ 4mg/kg and whether early prediction of dose escalation is possible by utilizing ultrasound inflammatory measures.

Key Dates

Start date
Sep 30, 2014
Status verified
May 2019
Primary completion
Apr 30, 2017
Completion
Apr 30, 2017

Study Design

Enrollment
74 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Tocilizumab
    All subjects will receive tocilizumab.

Primary Outcome Measure

Baseline to Month 3 Change in Total Power Doppler Synovitis Score of 34 Joints (Range 0 - 102) [ Time Frame: Baseline, 3 Month ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCLA David Geffen School of Medicine, Division of RheumatologyLos AngelesCalifornia90095-

Find similar trials in Los Angeles, CA

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
UCLA David Geffen School of Medicine, Division of Rheumatology· Los Angeles, CA

Related Studies